These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 25299893)
41. More on Merkel-Cell Carcinoma. Blom A; Saiag P N Engl J Med; 2016 Feb; 374(5):494-5. PubMed ID: 26840149 [No Abstract] [Full Text] [Related]
42. First PI3k inhibitor launches into crowded hematology markets. Morrison C Nat Biotechnol; 2014 Oct; 32(10):963-4. PubMed ID: 25299893 [No Abstract] [Full Text] [Related]
43. [CAL-101,a novel agent of targeted therapy in hematological malignancies]. Li CJ; Zhang Q; Zhang YZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):530-3. PubMed ID: 24763037 [TBL] [Abstract][Full Text] [Related]
44. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Castillo JJ; Furman M; Winer ES Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004 [TBL] [Abstract][Full Text] [Related]
46. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Fruman DA; Rommel C Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681 [TBL] [Abstract][Full Text] [Related]
47. PI3Kδ and PI3Kγ as targets for autoimmune and inflammatory diseases. Cushing TD; Metz DP; Whittington DA; McGee LR J Med Chem; 2012 Oct; 55(20):8559-81. PubMed ID: 22924688 [No Abstract] [Full Text] [Related]